Psoriatic Arthritis
From the Journals
Psoriatic arthritis activity spikes briefly postpartum
From the Journals
Infliximab biosimilar only moderately less expensive in Medicare Part D
Without biosimilar gap discounts in 2017, beneficiaries would have paid nearly $1,700 more in projected out-of-pocket costs for infliximab-dyyb...
From the Journals
Sustained minimal disease activity in PsA reduced CV risk factors
Achieving sustained minimal disease activity in psoriatic arthritis is associated with significant improvements in atherosclerotic disease risk...
From the Journals
Medication app boosts psoriasis patients’ short-term adherence
Adherence to daily topical psoriasis treatment improved significantly among patients who used a reminder app.
From the Journals
Risankizumab proves more effective in psoriasis than ustekinumab
Two phase 3 trials suggested that risankizumab can do more to improve quality of life, with similar safety.
From the Journals
Psoriasis registry study provides more data on infliximab’s infection risk
Infliximab was associated with a statistically significant increased risk of serious infection, compared with non-biologic systemic treatments.
From the Journals
AS inflammatory back pain criteria fall short in PsA
The presence or absence of back pain in patients with axial radiologic involvement did not affect prognosis, suggesting the value of considering...
Conference Coverage
Psoriasis pipeline is full of biologics
CHICAGO – “The IL-23 blockers are ideal for patients who want a few injections.”
News
FDA announces plan for biosimilar innovation and competition
One proposed step is to release a series of videos that explain key concepts about biosimilar and interchangeable products.
From the Journals
Extended data support ixekizumab for plaque psoriasis
An open-label, 4-year extension study of ixekizumab yields promising results.
Conference Coverage
Biosimilar switch accepted by most rheumatic disease patients
LIVERPOOL, ENGLAND – With health systems increasingly favoring biosimilars to biologics, the question is, are patients happy to make the switch?...